NCT03737565View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm)

CompletedOBSERVATIONAL

Enrollment

350

Participants

Timeline

Start Date

February 17, 2019

Primary Completion Date

January 2, 2025

Study Completion Date

January 2, 2025

Conditions

Coronary Artery Disease

Interventions

DEVICE

Optimax stent®

Percutaneous coronary intervention with Optimax stent®

Trial Locations (5)

10003

Hospital San Pedro de Alcántara, Cáceres

24080

Hospital Universitario de León, León

25198

Hospital Universitari Arnau de Vilanova, Lleida

06800

Hospital de Mérida, Mérida

08035

Hospital Universitario Vall d'Hebron, Barcelona

All Listed Sponsors

lead

Fundación EPIC

OTHER

NCT03737565 - Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) | Biotech Hunter | Biotech Hunter